Original Article

Blockade of the Bcr-Abl Kinase Activity Induces Apoptosis of Chronic Myelogenous Leukemia Cells by Suppressing Signal Transducer and Activator of Transcription 5–dependent Expression of Bcl-x_L

Correspondence to: Jose Luis Fernandez-Luna, Seccion de Inmunologia, Hospital Universitario Marques de Valdecilla, INSALUD, 39008 Santander, Spain. Tel:34-942-203453 Fax:34-942-203453 E-mail:inmflj{at}humv.es.

Released online: 13 March 2000

Bcr-Abl–expressing leukemic cells are highly resistant to apoptosis induced by chemotherapeutic drugs. Although a number of signaling molecules have been shown to be activated by the Bcr-Abl kinase, the antiapoptotic pathway triggered by this oncogene has not been elucidated. Here, we show that the interleukin 3-independent expression of the antiapoptotic protein, Bcl-x_L, is induced by Bcr-Abl through activation of signal transducer and activator of transcription (Stat)5. Inhibition of the Bcr-Abl kinase activity in Bcr-Abl–expressing cell lines and CD34⁺ cells from chronic myelogenous leukemia (CML) patients induces apoptosis by suppressing the capacity of Stat5 to interact with the bcl-x promoter. Interestingly, after inhibition of the Bcr-Abl kinase, the expression of Bcl-x_L is downregulated more rapidly in chronic phase than in blast crisis CML cells, suggesting an involvement of this protein in disease progression. Overall, we describe a novel antiapoptotic pathway triggered by Bcr-Abl that may contribute to the resistance of CML cells to undergo apoptosis.

Key Words: CGP 57148, cell death, blast crisis, promoter, interleukin 3

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Hallaert, D. Y. H., Jaspers, A., van Noesel, C. J., van Oers, M. H. J., Kater, A. P., Eldering, E. (2008). c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 112: 5141-5149 [Abstract] [Full Text]  
• Agirre, X., Jimenez-Velasco, A., San Jose-Eneriz, E., Garate, L., Bandres, E., Cordeu, L., Aparicio, O., Saez, B., Navarro, G., Vilas-Zornoza, A., Perez-Roger, I., Garcia-Foncillas, J., Torres, A., Heiniger, A., Calasanz, M. J., Fortes, P., Roman-Gomez, J., Prosper, F. (2008). Down-Regulation of hsa-miR-10a in Chronic Myeloid Leukemia CD34+ Cells Increases USF2-Mediated Cell Growth. Mol Cancer Res 6: 1830-1840 [Abstract] [Full Text]  
• Bewry, N. N., Nair, R. R., Emmons, M. F., Boulware, D., Pinilla-Ibarz, J., Hazlehurst, L. A. (2008). Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Molecular Cancer Therapeutics 7: 3169-3175 [Abstract] [Full Text]  
• Kurokawa, M., Zhao, C., Reya, T., Kornbluth, S. (2008). Inhibition of Apoptosome Formation by Suppression of Hsp90{beta} Phosphorylation in Tyrosine Kinase-Induced Leukemias. Mol. Cell. Biol. 28: 5494-5506 [Abstract] [Full Text]  
• Kavalerchik, E., Goff, D., Jamieson, C. H.M. (2008). Chronic Myeloid Leukemia Stem Cells. JCO 26: 2911-2915 [Abstract] [Full Text]  
• Katsoulidis, E., Sassano, A., Majchrzak-Kita, B., Carayol, N., Yoon, P., Jordan, A., Druker, B. J., Fish, E. N., Platanias, L. C. (2008). Suppression of Interferon (IFN)-inducible Genes and IFN-mediated Functional Responses in BCR-ABL-expressing Cells. J. Biol. Chem. 283: 10793-10803 [Abstract] [Full Text]  
• Harb, J. G., Chyla, B. I., Huettner, C. S. (2008). Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis. Blood 111: 3760-3769 [Abstract] [Full Text]  
• Chen, J.-L., Limnander, A., Rothman, P. B. (2008). Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene. Blood 111: 1677-1685 [Abstract] [Full Text]  
• Jamieson, C. H. (2008). Chronic Myeloid Leukemia Stem Cells. ASH Education Book 2008: 436-442 [Abstract] [Full Text]  
• Kuo, Y.-Y., Chang, Z.-F. (2007). GATA-1 and Gfi-1B Interplay To Regulate Bcl-xL Transcription. Mol. Cell. Biol. 27: 4261-4272 [Abstract] [Full Text]  
• Nam, S., Williams, A., Vultur, A., List, A., Bhalla, K., Smith, D., Lee, F. Y., Jove, R. (2007). Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Molecular Cancer Therapeutics 6: 1400-1405 [Abstract] [Full Text]  
• Wang, Y., Cai, D., Brendel, C., Barett, C., Erben, P., Manley, P. W., Hochhaus, A., Neubauer, A., Burchert, A. (2007). Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood 109: 2147-2155 [Abstract] [Full Text]  
• Yoon, P., Giafis, N., Smith, J., Mears, H., Katsoulidis, E., Sassano, A., Altman, J., Redig, A. J., Tallman, M. S., Platanias, L. C. (2006). Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells.. Molecular Cancer Therapeutics 5: 2815-2823 [Abstract] [Full Text]  
• Nagy, Z. S., Rui, H., Stepkowski, S. M., Karras, J., Kirken, R. A. (2006). A Preferential Role for STAT5, not Constitutively Active STAT3, in Promoting Survival of a Human Lymphoid Tumor. J. Immunol. 177: 5032-5040 [Abstract] [Full Text]  
• Kuroda, J., Puthalakath, H., Cragg, M. S., Kelly, P. N., Bouillet, P., Huang, D. C. S., Kimura, S., Ottmann, O. G., Druker, B. J., Villunger, A., Roberts, A. W., Strasser, A. (2006). Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc. Natl. Acad. Sci. USA 103: 14907-14912 [Abstract] [Full Text]  
• Kaufmann, S. H. (2006). Imatinib spells BAD news for Bcr/abl-positive leukemias. Proc. Natl. Acad. Sci. USA 103: 14651-14652 [Full Text]  
• Nelson, E. A., Walker, S. R., Li, W., Liu, X. S., Frank, D. A. (2006). Identification of Human STAT5-dependent Gene Regulatory Elements Based on Interspecies Homology. J. Biol. Chem. 281: 26216-26224 [Abstract] [Full Text]  
• Ye, D., Wolff, N., Li, L., Zhang, S., Ilaria, R. L. Jr (2006). STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood 107: 4917-4925 [Abstract] [Full Text]  
• Nguyen, T. K., Rahmani, M., Gao, N., Kramer, L., Corbin, A. S., Druker, B. J., Dent, P., Grant, S. (2006). Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.. Clin. Cancer Res. 12: 2239-2247 [Abstract] [Full Text]  
• Aichberger, K. J., Mayerhofer, M., Krauth, M.-T., Vales, A., Kondo, R., Derdak, S., Pickl, W. F., Selzer, E., Deininger, M., Druker, B. J., Sillaber, C., Esterbauer, H., Valent, P. (2005). Low-Level Expression of Proapoptotic Bcl-2-Interacting Mediator in Leukemic Cells in Patients with Chronic Myeloid Leukemia: Role of BCR/ABL, Characterization of Underlying Signaling Pathways, and Reexpression by Novel Pharmacologic Compounds. Cancer Res. 65: 9436-9444 [Abstract] [Full Text]  
• Parmar, S., Smith, J., Sassano, A., Uddin, S., Katsoulidis, E., Majchrzak, B., Kambhampati, S., Eklund, E. A., Tallman, M. S., Fish, E. N., Platanias, L. C. (2005). Differential regulation of the p70 S6 kinase pathway by interferon {alpha} (IFN{alpha}) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood 106: 2436-2443 [Abstract] [Full Text]  
• Appel, S., Balabanov, S., Brummendorf, T. H., Brossart, P. (2005). Effects of Imatinib on Normal Hematopoiesis and Immune Activation. Stem Cells 23: 1082-1088 [Abstract] [Full Text]  
• Andreu, E. J., Lledo, E., Poch, E., Ivorra, C., Albero, M. P., Martinez-Climent, J. A., Montiel-Duarte, C., Rifon, J., Perez-Calvo, J., Arbona, C., Prosper, F., Perez-Roger, I. (2005). BCR-ABL Induces the Expression of Skp2 through the PI3K Pathway to Promote p27Kip1 Degradation and Proliferation of Chronic Myelogenous Leukemia Cells. Cancer Res. 65: 3264-3272 [Abstract] [Full Text]  
• Aichberger, K. J., Mayerhofer, M., Krauth, M.-T., Skvara, H., Florian, S., Sonneck, K., Akgul, C., Derdak, S., Pickl, W. F., Wacheck, V., Selzer, E., Monia, B. P., Moriggl, R., Valent, P., Sillaber, C. (2005). Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 105: 3303-3311 [Abstract] [Full Text]  
• Rahmani, M., Reese, E., Dai, Y., Bauer, C., Kramer, L. B., Huang, M., Jove, R., Dent, P., Grant, S. (2005). Cotreatment with Suberanoylanilide Hydroxamic Acid and 17-Allylamino 17-demethoxygeldanamycin Synergistically Induces Apoptosis in Bcr-Abl+ Cells Sensitive and Resistant to STI571 (Imatinib Mesylate) in Association with Down-Regulation of Bcr-Abl, Abrogation of Signal Transducer and Activator of Transcription 5 Activity, and Bax Conformational Change. Mol. Pharmacol. 67: 1166-1176 [Abstract] [Full Text]  
• Deming, P. B., Schafer, Z. T., Tashker, J. S., Potts, M. B., Deshmukh, M., Kornbluth, S. (2004). Bcr-Abl-Mediated Protection from Apoptosis Downstream of Mitochondrial Cytochrome c Release. Mol. Cell. Biol. 24: 10289-10299 [Abstract] [Full Text]  
• O'Hare, T., Pollock, R., Stoffregen, E. P., Keats, J. A., Abdullah, O. M., Moseson, E. M., Rivera, V. M., Tang, H., Metcalf, C. A. III, Bohacek, R. S., Wang, Y., Sundaramoorthi, R., Shakespeare, W. C., Dalgarno, D., Clackson, T., Sawyer, T. K., Deininger, M. W., Druker, B. J. (2004). Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 104: 2532-2539 [Abstract] [Full Text]  
• Dai, Y., Rahmani, M., Corey, S. J., Dent, P., Grant, S. (2004). A Bcr/Abl-independent, Lyn-dependent Form of Imatinib Mesylate (STI-571) Resistance Is Associated with Altered Expression of Bcl-2. J. Biol. Chem. 279: 34227-34239 [Abstract] [Full Text]  
• Dai, Y., Rahmani, M., Pei, X.-Y., Dent, P., Grant, S. (2004). Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood 104: 509-518 [Abstract] [Full Text]  
• Uchida, M., Watanabe, T., Kunitama, M., Mori, M., Kikuchi, S., Yoshida, K., Kirito, K., Nagai, T., Ozawa, K., Komatsu, N. (2004). Erythropoietin Overcomes Imatinib-Induced Apoptosis and Induces Erythroid Differentiation in TF-1/bcr-abl Cells. Stem Cells 22: 609-616 [Abstract] [Full Text]  
• Calabretta, B., Perrotti, D. (2004). The biology of CML blast crisis. Blood 103: 4010-4022 [Abstract] [Full Text]  
• Coluccia, A. M. L., Perego, S., Cleris, L., Gunby, R. H., Passoni, L., Marchesi, E., Formelli, F., Gambacorti-Passerini, C. (2004). Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo. Blood 103: 2787-2794 [Abstract] [Full Text]  
• Gonzalez, I., Andreu, E. J., Panizo, A., Inoges, S., Fontalba, A., Fernandez-Luna, J. L., Gaboli, M., Sierrasesumaga, L., Martin-Algarra, S., Pardo, J., Prosper, F., de Alava, E. (2004). Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis. Clin. Cancer Res. 10: 751-761 [Abstract] [Full Text]  
• Bartolovic, K., Balabanov, S., Hartmann, U., Komor, M., Boehmler, A. M., Buhring, H.-J., Mohle, R., Hoelzer, D., Kanz, L., Hofmann, W.-K., Brummendorf, T. H. (2004). Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 103: 523-529 [Abstract] [Full Text]  
• Ferrao, P. T., Frost, M. J., Siah, S.-P., Ashman, L. K. (2003). Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. Blood 102: 4499-4503 [Abstract] [Full Text]  
• Mohapatra, S., Chu, B., Wei, S., Djeu, J., Epling-Burnette, P. K., Loughran, T., Jove, R., Pledger, W. J. (2003). Roscovitine Inhibits STAT5 Activity and Induces Apoptosis in the Human Leukemia Virus Type 1-Transformed Cell Line MT-2. Cancer Res. 63: 8523-8530 [Abstract] [Full Text]  
• Vlahovic, G., Crawford, J. (2003). Activation of Tyrosine Kinases in Cancer. The Oncologist 8: 531-538 [Abstract] [Full Text]  
• Minami, Y., Yamamoto, K., Kiyoi, H., Ueda, R., Saito, H., Naoe, T. (2003). Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. Blood 102: 2969-2975 [Abstract] [Full Text]  
• Wohlbold, L., van der Kuip, H., Miething, C., Vornlocher, H.-P., Knabbe, C., Duyster, J., Aulitzky, W. E. (2003). Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 102: 2236-2239 [Abstract] [Full Text]  
• Faderl, S., Harris, D., Van, Q., Kantarjian, H. M., Talpaz, M., Estrov, Z. (2003). Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. Blood 102: 630-637 [Abstract] [Full Text]  
• Wong, S., McLaughlin, J., Cheng, D., Witte, O. N. (2003). Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors. Blood 101: 4088-4097 [Abstract] [Full Text]  
• Benekli, M., Baer, M. R., Baumann, H., Wetzler, M. (2003). Signal transducer and activator of transcription proteins in leukemias. Blood 101: 2940-2954 [Abstract] [Full Text]  
• Hietakangas, V., Poukkula, M., Heiskanen, K. M., Karvinen, J. T., Sistonen, L., Eriksson, J. E. (2003). Erythroid Differentiation Sensitizes K562 Leukemia Cells to TRAIL-Induced Apoptosis by Downregulation of c-FLIP. Mol. Cell. Biol. 23: 1278-1291 [Abstract] [Full Text]  
• Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R., Talpaz, M. (2003). BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101: 690-698 [Abstract] [Full Text]  
• Jiang, X., Ng, E., Yip, C., Eisterer, W., Chalandon, Y., Stuible, M., Eaves, A., Eaves, C. J. (2002). Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo. Blood 100: 3731-3740 [Abstract] [Full Text]  
• Mayerhofer, M., Valent, P., Sperr, W. R., Griffin, J. D., Sillaber, C. (2002). BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha , through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100: 3767-3775 [Abstract] [Full Text]  
• Kazi, A., Smith, D. M., Zhong, Q., Dou, Q. P. (2002). Inhibition of Bcl-XL Phosphorylation by Tea Polyphenols or Epigallocatechin-3-Gallate Is Associated with Prostate Cancer Cell Apoptosis. Mol. Pharmacol. 62: 765-771 [Abstract] [Full Text]  
• Hinz, M., Lemke, P., Anagnostopoulos, I., Hacker, C., Krappmann, D., Mathas, S., Dorken, B., Zenke, M., Stein, H., Scheidereit, C. (2002). Nuclear Factor {kappa}B-dependent Gene Expression Profiling of Hodgkin's Disease Tumor Cells, Pathogenetic Significance, and Link to Constitutive Signal Transducer and Activator of Transcription 5a Activity. JEM 196: 605-617 [Abstract] [Full Text]  
• Slupianek, A., Hoser, G., Majsterek, I., Bronisz, A., Malecki, M., Blasiak, J., Fishel, R., Skorski, T. (2002). Fusion Tyrosine Kinases Induce Drug Resistance by Stimulation of Homology-Dependent Recombination Repair, Prolongation of G2/M Phase, and Protection from Apoptosis. Mol. Cell. Biol. 22: 4189-4201 [Abstract] [Full Text]  
• Nieborowska-Skorska, M., Hoser, G., Kossev, P., Wasik, M. A., Skorski, T. (2002). Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. Blood 99: 4531-4539 [Abstract] [Full Text]  
• Holtz, M. S., Slovak, M. L., Zhang, F., Sawyers, C. L., Forman, S. J., Bhatia, R. (2002). Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99: 3792-3800 [Abstract] [Full Text]  
• Iervolino, A., Santilli, G., Trotta, R., Guerzoni, C., Cesi, V., Bergamaschi, A., Gambacorti-Passerini, C., Calabretta, B., Perrotti, D. (2002). hnRNP A1 Nucleocytoplasmic Shuttling Activity Is Required for Normal Myelopoiesis and BCR/ABL Leukemogenesis. Mol. Cell. Biol. 22: 2255-2266 [Abstract] [Full Text]  
• Baron, F., Turhan, A. G., Giron-Michel, J., Azzarone, B., Bentires-Alj, M., Bours, V., Bourhis, J. H., Chouaib, S., Caignard, A. (2002). Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood 99: 2107-2113 [Abstract] [Full Text]  
• Sonoyama, J., Matsumura, I., Ezoe, S., Satoh, Y., Zhang, X., Kataoka, Y., Takai, E., Mizuki, M., Machii, T., Wakao, H., Kanakura, Y. (2002). Functional Cooperation among Ras, STAT5, and Phosphatidylinositol 3-Kinase Is Required for Full Oncogenic Activities of BCR/ABL in K562 Cells. J. Biol. Chem. 277: 8076-8082 [Abstract] [Full Text]  
• Dorsey, J. F., Cunnick, J. M., Mane, S. M., Wu, J. (2002). Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl+ K562 leukemic cells by Gab2. Blood 99: 1388-1397 [Abstract] [Full Text]  
• Mow, B. M. F., Chandra, J., Svingen, P. A., Hallgren, C. G., Weisberg, E., Kottke, T. J., Narayanan, V. L., Litzow, M. R., Griffin, J. D., Sausville, E. A., Tefferi, A., Kaufmann, S. H. (2002). Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 99: 664-671 [Abstract] [Full Text]  
• Yu, C., Krystal, G., Varticovksi, L., McKinstry, R., Rahmani, M., Dent, P., Grant, S. (2002). Pharmacologic Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase/Mitogen-activated Protein Kinase Inhibitors Interact Synergistically with STI571 to Induce Apoptosis in Bcr/Abl-expressing Human Leukemia Cells. Cancer Res. 62: 188-199 [Abstract] [Full Text]  
• Ghaffari, S., Kitidis, C., Fleming, M. D., Neubauer, H., Pfeffer, K., Lodish, H. F. (2001). Erythropoiesis in the absence of janus-kinase 2: BCR-ABL induces red cell formation in JAK2-/- hematopoietic progenitors. Blood 98: 2948-2957 [Abstract] [Full Text]  
• Wolff, N. C., Ilaria, R. L. Jr (2001). Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood 98: 2808-2816 [Abstract] [Full Text]  
• Goetz, A. W., van der Kuip, H., Maya, R., Oren, M., Aulitzky, W. E. (2001). Requirement for Mdm2 in the Survival Effects of Bcr-Abl and Interleukin 3 in Hematopoietic Cells. Cancer Res. 61: 7635-7641 [Abstract] [Full Text]  
• van der Kuip, H., Goetz, A. W., Miething, C., Duyster, J., Aulitzky, W. E. (2001). Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis. Blood 98: 1532-1541 [Abstract] [Full Text]  
• Cetkovic-Cvrlje, M., Roers, B. A., Waurzyniak, B., Liu, X.-P., Uckun, F. M. (2001). Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice. Blood 98: 1607-1613 [Abstract] [Full Text]  
• Di Pietro, R., Secchiero, P., Rana, R., Gibellini, D., Visani, G., Bemis, K., Zamai, L., Miscia, S., Zauli, G. (2001). Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1. Blood 97: 2596-2603 [Abstract] [Full Text]  
• Donato, N. J., Wu, J. Y., Zhang, L., Kantarjian, H., Talpaz, M. (2001). Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor {beta}-chain in BCR-ABL+ human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. Blood 97: 2846-2853 [Abstract] [Full Text]  
• Chen, H., Lee, J. M., Zong, Y., Borowitz, M., Ng, M. H., Ambinder, R. F., Hayward, S. D. (2001). Linkage between STAT Regulation and Epstein-Barr Virus Gene Expression in Tumors. J. Virol. 75: 2929-2937 [Abstract] [Full Text]  
• Hasinoff, B. B., Abram, M. E., Barnabé, N., Khélifa, T., Allan, W. P., Yalowich, J. C. (2001). The Catalytic DNA Topoisomerase II Inhibitor Dexrazoxane (ICRF-187) Induces Differentiation and Apoptosis in Human Leukemia K562 Cells. Mol. Pharmacol. 59: 453-461 [Abstract] [Full Text]  
• Deininger, M. W. N., Goldman, J. M., Melo, J. V. (2000). The molecular biology of chronic myeloid leukemia. Blood 96: 3343-3356 [Full Text]  
• Kabarowski, J. H. S., Witte, O. N. (2000). Consequences of BCR-ABL Expression within the Hematopoietic Stem Cell in Chronic Myeloid Leukemia. Stem Cells 18: 399-408 [Abstract] [Full Text]  
• Gambacorti-Passerini, C., Barni, R., le Coutre, P., Zucchetti, M., Cabrita, G., Cleris, L., Rossi, F., Gianazza, E., Brueggen, J., Cozens, R., Pioltelli, P., Pogliani, E., Corneo, G., Formelli, F., D'Incalci, M. (2000). Role of {alpha}1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL+ Leukemic Cells to the Abl Inhibitor STI571. JNCI J Natl Cancer Inst 92: 1641-1650 [Abstract] [Full Text]  
• Gesbert, F., Griffin, J. D. (2000). Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 96: 2269-2276 [Abstract] [Full Text]  
• Ehret, G. B., Reichenbach, P., Schindler, U., Horvath, C. M., Fritz, S., Nabholz, M., Bucher, P. (2001). DNA Binding Specificity of Different STAT Proteins. COMPARISON OF IN VITRO SPECIFICITY WITH NATURAL TARGET SITES. J. Biol. Chem. 276: 6675-6688 [Abstract] [Full Text]  
• Masuda, A., Matsuguchi, T., Yamaki, K., Hayakawa, T., Yoshikai, Y. (2001). Interleukin-15 Prevents Mouse Mast Cell Apoptosis through STAT6-mediated Bcl-xL Expression. J. Biol. Chem. 276: 26107-26113 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS